Regarding labeled nanoparticles, both T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5, present similar receptor specificity in cell culture (Figure 3C) and similar loss of targeting capacity in both human CXCR4+ cancer mouse models in vivo (Figure 4 and Figure 5). The gene discussed is CXCR4; the disease is cancer.